Hospitals & Healthcare InfrastructureMedanta reports 33.6% revenue growth and approves ₹997 crore, 500-bed Ghaziabad hospital
3 November 2026 | India
Global Health Limited (Medanta) reported Q2 FY27 revenue of ₹1,469 crore, up 33.6% year-on-year, and operating EBITDA of ₹370.1 crore, up 60.2%. Network census beds increased from 2,658 to 3,115, with occupancy improving from 64% to 67%. The network had 3,811 installed beds as of 30 September 2026. The board approved a proposed 500-bed super-speciality hospital in Ghaziabad, with estimated investment of ₹997 crore including land. A 2.61-acre site was acquired at auction for ₹165.82 crore. The new hospital is planned capacity, not yet operational.
Source: Medanta
Strategic Watch
Watch the distinction between 3,811 installed beds, 3,115 census beds and the proposed 500 beds. Track commissioning milestones, specialty mix, staffing and catchment-area demand before treating approved investment as revenue-generating capacity.
GreyRadius Insight
Evaluate the ₹997 crore Ghaziabad commitment against realistic time-to-opening, physician recruitment and referral capture. Model occupancy ramp and return on invested capital separately from current-network growth.
Hospitals & DiagnosticsFortis Healthcare reports 17.3% revenue growth to ₹2,735 crore as hospital profitability moderates
5 November 2026 | India
Fortis Healthcare reported consolidated Q2 FY27 revenue of ₹2,735 crore, up 17.3% year-on-year. Hospital revenue increased 18.6% to ₹2,340 crore. Diagnostics gross revenue grew 12.2% to ₹448 crore, while net diagnostics revenue after intercompany eliminations was ₹394 crore. Consolidated profit after tax declined 2.5% to approximately ₹320 crore and PAT margin fell from 14.1% to 11.7%. Hospital PAT margin declined from 14.5% to 12.1%, while diagnostics PAT margin improved from 14.8% to 15.2%. The quarter combines demand growth with margin pressure in hospitals.
Source: Fortis Healthcare
Strategic Watch
Track whether hospital margin compression reflects case mix, personnel costs, new-facility ramp-up or pricing. Diagnostics margin improvement should be assessed separately; revenue growth alone does not demonstrate stronger unit economics.
GreyRadius Insight
Build a service-line profitability bridge linking patient volumes, realisations, clinician productivity and costs. Prioritise profitable capacity utilisation and care pathways over headline revenue expansion.
Hospitals, Capacity & InvestmentYatharth Hospitals reports 52% revenue growth, with operational census beds reaching 1,820
3 November 2026 | India
Yatharth Hospital & Trauma Care Services reported Q2 FY27 revenue of ₹431.4 crore, up 52% year-on-year, and EBITDA of ₹102 crore, up 50%, at a 23.6% EBITDA margin. Profit after tax rose 17% to ₹48.5 crore. The network reported total bed capacity exceeding 2,800, including a 250-bed Gurugram hospital under construction, versus 1,820 operational census beds. Occupancy was 72% of operational census beds, while average revenue per occupied bed increased 11% to ₹35,948. The company also highlighted its strategic investment relationship with Advent and ongoing expansion plans.
Source: Yatharth Hospitals | Yatharth Hospitals
Strategic Watch
Separate operational census beds from the more than 2,800-bed capacity pipeline. Watch commissioning and clinical staffing, occupancy by facility, ARPOB sustainability and whether EBITDA growth converts into cash generation.
GreyRadius Insight
Use facility-level ramp-up economics to determine expansion sequencing. An 11% increase in revenue per occupied bed is useful only alongside case-mix quality, length of stay, referral conversion and incremental operating cost.
Pharmaceuticals, Oncology & Regulatory ApprovalsFDA grants accelerated approval to Rybrevant Faspro for recurrent or metastatic head and neck cancer
5 November 2026 | United States
The U.S. FDA granted accelerated approval to Janssen Biotech’s Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for adults with recurrent or metastatic head and neck squamous cell carcinoma following platinum-based chemotherapy and immunotherapy. The indication excludes HPV-associated oropharyngeal cancer. In an open-label multicentre study of 102 patients, overall response rate was 42%; among responders, 56% maintained responses for at least six months. The decision relies on tumour response and duration rather than an established survival benefit, and continued approval may depend on confirmatory studies. Important risks include administration-related reactions, pneumonitis, skin toxicity and ocular toxicity.
Source: U.S. FDA
Strategic Watch
Track confirmatory-study progress and whether response durability translates into meaningful patient outcomes. Monitor indication restrictions, adverse-event management and coverage decisions; accelerated approval is not evidence of established overall-survival benefit.
GreyRadius Insight
Market access depends on more than regulatory clearance. Map oncology referral pathways, biomarker/eligibility checks, treatment-site readiness and payer coverage, while collecting real-world safety and persistence evidence.
Cell & Gene Therapy Manufacturing RegulationFDA finalises potency-assurance guidance to strengthen cell and gene therapy development and manufacturing
2 November 2026 | United States
The U.S. FDA issued final guidance recommending a comprehensive, risk-based Potency Assurance Strategy for cellular and gene therapy products, replacing its 2011 potency-testing guidance. It addresses raw-material quality, manufacturing variability, biologically relevant potency assays, release testing and lifecycle verification. The recommendations cover viral-vector therapies, patient-specific products and therapies with short shelf lives. The objective is to demonstrate consistent product quality through clinical development, licensing and post-approval manufacturing. The guidance does not approve any specific therapy. The FDA scheduled an implementation webinar for 10 December 2026.
Source: U.S. FDA
Strategic Watch
Watch how developers translate the guidance into validated assays, batch-release specifications and lifecycle comparability evidence. Product-specific regulatory expectations and implementation costs may vary considerably.
GreyRadius Insight
Treat potency assurance as an integrated CMC and manufacturing-design decision, not a late-stage testing task. Align assay development, process controls, supplier qualification and batch-disposition evidence before scale-up.